Where can Adocia fit in the diabetes market?

Dr. Remi Soula, co-founder and director of business development and intellectual property at Adocia, chats with Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about being a smaller business in the highly competitive diabetes space. He explains more about Adocia's business model, the company's pipeline technology, and their ongoing partnership with diabetes giant, Eli Lilly. Adocia's clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a fast-acting formulation of human insulin (HinsBet U100), and a combination of slow-acting insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing a concentrated formulation of human insulin (HinsBet U500).

Interviewer: Mike Ward – Global Director of Content, Pharma Intelligence, In Vivo/Pink Sheet/Scrip
Interviewee: Remi Soula – Director Business Development and Intellectual Property, Adocia